Did you know?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) dropped 7.5% during mid-day trading on Friday . The company traded as low as $12.43 and last traded at $12.43. Approximately ...Nov 30, 2023 · NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News & Analysis Should You Buy or Sell Catalyst Pharmaceuticals Stock? Get The Latest CPRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Should You Buy or Sell Catalyst Pharmaceuticals Stock? Dec 4, 2023 · CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ... Catalyst Pharmaceutical (CPRX) closed at $16.60 in the latest trading session, marking a -0.12% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.7%.Find the latest on option chains for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.That number of contracts represents approximately 884,100 underlying shares, working out to a sizeable 52.9% of CPRX's average daily trading volume over the past month, of 1.7 million shares.(Nasdaq: CPRX) announced today that it has entered into definitive agreements to sell (i) 4.0 million shares of the Company's common stock, and (ii) common ...Right now, Catalyst has an S/TA ratio of 0.71, which means that the company gets $0.71 in sales for each dollar in assets. Comparing this to the industry average of 0.27, it can be said that the ...CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours...Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.70. If an investor was to purchase shares of CPRX stock at the current price ...The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies. Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ...Find the latest dividend history for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.A couple of Nasdaq stocks saw particularly sharp declines Wednesday morning that stemmed from bad news in their respective businesses. American Airlines Group ( AAL 3.66%) warned that its first ...Catalyst Pharmaceuticals (NASDAQ:CPRX) has recently experienced a trading halt on the Nasdaq exchange, leaving investors eagerly awaiting pending news. The specific cause for this halt remains undisclosed, however, it is widely anticipated that it revolves around the potential disclosure of significant information.Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Fintel reports that on August 22, 2023, Cantor FitzgeRead more to see why CPRX stock is a Strong Buy. Catalys Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with rare neuromuscular and neurological diseases.The company reported a solid second-quarter result, with total revenues growing 87.5% year-over-year to an all-time high of … CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSW CPRX: NASDAQ (Stock) CATALYST PHARMACEUTICALS, INC. DEC 01, 11:00 AM EST $14.82 +0% Dividend (Fwd) $0.00 Yield (Fwd) Annualized forward dividend yield. Multiplies the ... NasdaqCM:CPRX Earnings and Revenue Growth August 25th 2022

A commercial-stage biopharmaceutical firm, Catalyst Pharmaceuticals (NASDAQ:CPRX) focuses on developing and commercializing innovative therapies for people with rare debilitating, chronic ...CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …Market forces rained on the parade of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shareholders today, when the analysts downgraded their forecasts for next year. There was a fairly draconian cut ...... Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza ...Feb 27, 2023 · For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...

Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Greetings and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2022 ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Catalyst Pharmaceuticals last released its quarterly earnings data o. Possible cause: Swiss National Bank raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:.